Compare NGVC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVC | CMPS |
|---|---|---|
| Founded | 1955 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.4M | 611.6M |
| IPO Year | 2012 | 2020 |
| Metric | NGVC | CMPS |
|---|---|---|
| Price | $25.20 | $6.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.43 |
| AVG Volume (30 Days) | 370.8K | ★ 1.4M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $1,330,836,000.00 | N/A |
| Revenue This Year | $7.83 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | ★ 7.19 | N/A |
| 52 Week Low | $24.00 | $2.25 |
| 52 Week High | $61.22 | $7.13 |
| Indicator | NGVC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 32.97 | 59.67 |
| Support Level | $24.29 | $6.08 |
| Resistance Level | $26.32 | $7.13 |
| Average True Range (ATR) | 1.08 | 0.40 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 34.28 | 73.09 |
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.